Efficacy of the Use of Refrigerant Helmet to Prevent Alopecia in Patients Treated With Eribulin for Breast Cancer

Centre Oscar Lambret23 enrolled

Overview

HALACAP-1406 is a prospective single-centre non-interventional study assessing the refrigerant helmet use as medical device to prevent alopecia induced by eribulin (Halaven®) in the conditions of use specified in its marketing authorization. Eribulin will be used alone for the treatment of the patients having a locally advanced or metastatic breast cancer which have progressed after at least 1 chemotherapy regimen for their advanced stage.

A nurse will meet the patient and present the study, then the patient will be invited to participate. If the patient is interested, an information note will be given and the non-opposition of the patient will be collected. Patients will be registered via a registration form and an inclusion number will be attributed at each patient. Eribulin will be used within the framework of its marketing authorization, per cycle of 21 days, at day 1 and day 8. Modalities of refrigerant helmet use will be set according to the habits of the Oscar Lambret center with the following rules : * Placement of a single-use non-woven hygiene cap on the scalp * T-15 minutes: placement of the refrigerant helmet * T0: begin of eribulin infusion (duration: 2-5 minutes) * T+15 minutes: rinse of the line * T+30 minutes: withdrawal of the helmet Efficacy will be evaluated before treatment and at each eribulin cycle.

Study Type

OBSERVATIONAL

Enrollment

Conditions

Breast Cancer Metastatic Breast Cancer

Eligibility

Sex: FEMALEMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Female patient who has a locally advanced or metastatic breast cancer * Indication of Halaven treatment : patient pretreated with anthracyclines or taxanes, patient who has received at least 1 chemotherapy regimen for their advanced or metastatic stage * Patient who has had enough time to have retrieved her hair or whose last chemotherapy regimen didn't induce alopecia. * Aged ≥ 18 years * Non-opposition of the patient must have been collected Exclusion Criteria: * Skin metastasis of the scalp * Sensitivity to cold, cold agglutinin disease or cryoglobulinemia * Impossibility to submit at the study procedures due to geographic, social or mental reasons

Locations (1)

Centre Oscar Lambret

Lille, France

Outcomes

Primary Outcomes

Alopecia grade after 3 cycles of eribulin according to NCI-CTCAE v4.0

Efficacy of the refrigerant helmet : Alopecia grade after 3 cycles of eribulin

Time frame: on the day 1 of cycle 4

Secondary Outcomes

Adverse events graded according to NCI-CTCAE v4.0

Tolerance of the refrigerant helmet : graduation of adverse events lived by patients

Time frame: every 28 days : at day 1 of each cycle during 3 cycles

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.